WASHINGTON, August 1 /PRNewswire-USNewswire/ -- Mark Merritt, President of the Pharmaceutical Care Management Association, issued the following statement in response to new comparative effectiveness legislation introduced late this week by Senate Finance Committee Chair Max Baucus (D-Mont.) and Senate Budget Committee Chair Kent Conrad (D-N.D.):
"We applaud Senators Baucus and Conrad for helping advance the discussion about how best to improve quality through more objective information and to foster value-based purchasing. We look forward to reviewing the Baucus-Conrad legislation in greater detail and working collaboratively with them and other stakeholders in this area.
"PBMs have been at the forefront of efforts to bring more measurement, accountability, and real-time information to the health care system. PCMA believes comparing the clinical effectiveness of competing drug therapies is an important tool in promoting value-based purchasing. Pharmacy benefit managers have led the way with pharmacy & therapeutics (P&T) committees and a wide range of proven utilization tools--including multi-tier formularies and step therapy--to ensure patients have access to cost-effective and clinically proven prescription drugs."
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D.
|SOURCE Pharmaceutical Care Management Association|
Copyright©2008 PR Newswire.
All rights reserved